Vor Biopharma Inc. (NASDAQ:VOR) Given Consensus Rating of “Moderate Buy” by Brokerages

Vor Biopharma Inc. (NASDAQ:VOR) has been assigned an average rating of “Moderate Buy” from the fourteen ratings firms that are covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating, seven have issued a buy rating and one has issued a strong buy rating on the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $66.1250.

A number of research analysts have commented on VOR shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vor Biopharma in a research report on Wednesday, October 8th. Stifel Nicolaus upgraded Vor Biopharma from a “hold” rating to a “buy” rating and set a $55.00 target price on the stock in a research note on Wednesday, September 24th. Wedbush assumed coverage on Vor Biopharma in a research report on Tuesday, November 25th. They set a “neutral” rating for the company. TD Cowen began coverage on Vor Biopharma in a research report on Wednesday, December 17th. They issued a “buy” rating for the company. Finally, Citigroup started coverage on Vor Biopharma in a research report on Friday, January 9th. They issued a “buy” rating and a $50.00 price objective on the stock.

Insiders Place Their Bets

In related news, Director Ra Capital Management, L.P. sold 24,579 shares of the business’s stock in a transaction on Thursday, October 30th. The shares were sold at an average price of $25.12, for a total value of $617,424.48. Following the sale, the director owned 779,652 shares in the company, valued at approximately $19,584,858.24. The trade was a 3.06% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders have sold a total of 621,574 shares of company stock valued at $16,574,179 in the last quarter. Insiders own 0.45% of the company’s stock.

Institutional Investors Weigh In On Vor Biopharma

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Fcpm Iii Services B.V. purchased a new stake in shares of Vor Biopharma in the third quarter worth approximately $18,496,000. Jane Street Group LLC acquired a new position in shares of Vor Biopharma during the first quarter valued at about $140,000. Millennium Management LLC grew its holdings in shares of Vor Biopharma by 122.5% during the third quarter. Millennium Management LLC now owns 24,764 shares of the company’s stock valued at $1,207,000 after buying an additional 134,764 shares during the last quarter. Ariose Capital Management Ltd purchased a new position in shares of Vor Biopharma in the third quarter worth about $5,368,000. Finally, Goldman Sachs Group Inc. boosted its holdings in shares of Vor Biopharma by 218.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company’s stock valued at $61,000 after acquiring an additional 58,247 shares during the last quarter. Hedge funds and other institutional investors own 97.29% of the company’s stock.

Vor Biopharma Price Performance

VOR opened at $17.60 on Wednesday. The firm has a market cap of $183.22 million, a price-to-earnings ratio of -0.05 and a beta of 2.02. The stock’s 50 day simple moving average is $11.55 and its 200 day simple moving average is $27.63. Vor Biopharma has a 1 year low of $2.62 and a 1 year high of $65.80.

About Vor Biopharma

Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company’s proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient’s immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.

The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).